content: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(d) OF
                             THE SECURITIES ACT OF 1934
  
           Date of report (Date of earliest event reported): May 29, 2002
                                                             ------------
  
  
                                 CYTOGEN CORPORATION
                                 -------------------
                 (Exact Name of Registrant as Specified in Charter)
  
  
             Delaware                     000-14879                 222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction     (Commission File Number)       (IRS Employer
        of Incorporation)                                      Identification No.)
  
  
  600 College Road East, CN 5308, Princeton, NJ                            08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                              (Zip Code)
  
  
  
                                   (609) 750-8200
                  ------------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
  
            -------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  <PAGE>
  
  
       Item 5.     Other Events.
  
       On May 29, 2002, Cytogen Corporation (the "Company") issued a press release
  reporting the Company's financial guidance and outlining the Company's strategic
  planning and  operations  for 2002.  Subsequently,  on May 30, 2002, the Company
  issued a joint  press  release  with  Draximage  Inc.,  the  radiopharmaceutical
  subsidiary  of DRAXIS  Health  Inc.,  announcing  the launch of DRAXIS  Health's
  BrachySeed  Palladium-103  product in the United  States  for the  treatment  of
  prostate cancer.
  
       Each such press  release is  attached  hereto as Exhibit  99.1 and  Exhibit
  99.2, respectively,  and each is incorporated herein by reference. The foregoing
  description of each such press release is qualified in its entirety by reference
  to each such respective document.
  
       Item 7.    Financial Statements, Pro Forma Financial Information and
  Exhibits.
  
       (c) Exhibits.
  
             Exhibit No.       Description
             -----------       -----------
             99.1              Press release of the Company dated May 29, 2002
             99.2              Press release of the Company dated May 30, 2002
  
  
  <PAGE>
  
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                Cytogen Corporation
  
  
  
                                                By: /s/ Lawrence R. Hoffman
                                                    ------------------------------
                                                    Lawrence R. Hoffman,
                                                     Chief Financial Officer
  
  
  Date:  May 30, 2002
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "final_form8-k052902.txt", "description": "CYTOGEN CORP. FORM 8-K DATED MAY 29, 2002", "secsgml_size_bytes": 3416}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "02666778"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                                Washington, DC 20549
  
                           -------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                         PURSUANT TO SECTION 13 OR 15(d) OF
                             THE SECURITIES ACT OF 1934
  
           Date of report (Date of earliest event reported): May 29, 2002
                                                             ------------
  
                                 CYTOGEN CORPORATION
                                 -------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 222322400
  --------------------------------------------------------------------------------
  (State or Other Jurisdiction     (Commission File Number)       (IRS Employer
        of Incorporation)                                      Identification No.)
  
  600 College Road East, CN 5308, Princeton, NJ                            08540
  --------------------------------------------------------------------------------
  (Address of Principal Executive Offices)                              (Zip Code)
  
                                   (609) 750-8200
                  ------------------------------------------------
                           (Registrant's telephone number,
                                including area code)
  
            -------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  Item 5.     Other Events.
  
       On May 29, 2002, Cytogen Corporation (the "Company") issued a press release
  reporting the Company's financial guidance and outlining the Company's strategic
  planning and  operations  for 2002.  Subsequently,  on May 30, 2002, the Company
  issued a joint  press  release  with  Draximage  Inc.,  the  radiopharmaceutical
  subsidiary  of DRAXIS  Health  Inc.,  announcing  the launch of DRAXIS  Health's
  BrachySeed  Palladium-103  product in the United  States  for the  treatment  of
  prostate cancer.
  
       Each such press  release is  attached  hereto as Exhibit  99.1 and  Exhibit
  99.2, respectively,  and each is incorporated herein by reference. The foregoing
  description of each such press release is qualified in its entirety by reference
  to each such respective document.
  
       Item 7.    Financial Statements, Pro Forma Financial Information and
  Exhibits.
  
       (c) Exhibits.
  
             Exhibit No.       Description
             -----------       -----------
             99.1              Press release of the Company dated May 29, 2002
             99.2              Press release of the Company dated May 30, 2002
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                Cytogen Corporation
  
                                                By: /s/ Lawrence R. Hoffman
                                                    ------------------------------
                                                    Lawrence R. Hoffman,
                                                     Chief Financial Officer
  
  Date:  May 30, 2002